N/A
N=18
Treatment of Suicidal Ideation With Intravenous Ketamine Infusion
Depression · Suicidal Ideation
Bottom Line
View on ClinicalTrials.gov: NCT01887990 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jul 2015
Primary outcome: Primary: Suicidality — 7.3; 21.5; 18.0; 0 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ketamine (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- University of Alabama at Birmingham
- Primary completion
- Jan 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Suicidality |
7.3; 21.5; 18.0; 0 | — |
| SECONDARY Depression |
43.9; 59.4; 22.5; 12.5 | — |
Summary
This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression.
Eligibility Criteria
Inclusion Criteria
- Age : 19-64
- Significant suicidality score on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Willing and able to provide informed consent.
- Individuals with current substance abuse are allowed
Exclusion Criteria
- Pregnant or lactating; women of reproductive potential must have a negative urine pregnancy test (urine dipstick method)
- Post-Partum state : defined as being within 2 months of delivery or miscarriage
- Homicide risk as determined by clinical interview
- Treatment with any medication known to specifically target the glutamate-NMDA receptor system (ie lamotrigine, acamprosate, memantine, riluzole or lithium)
- Any known hypersensitivity or serious adverse effect associated with ketamine treatment.
- Any clinically significant medical condition or therapy that would preclude treatment with ketamine, to include recent myocardial infarction or unstable angina
- Medically unstable, including acute withdrawal from alcohol or benzodiazepines requiring the use of benzodiazepine treatment.
- Any of the following DSM-IV diagnoses or categories:
- Any current psychosis or history of a non-mood psychotic disorder (e.g., schizophrenia)
- Currently in a manic or mixed episode
- Current use (defined by urine dipstick test) or abuse of hallucinogenic drugs (except marijuana) such as phencyclidine
- Any dissociative disorder
- Any pervasive developmental disorder (e.g., autism)
- A cognitive disorder (e.g., Alzheimer's Disease)
- Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster B and C personality disorders may be included
- Any eating disorder
Data sourced from ClinicalTrials.gov (NCT01887990). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.